Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10439558 | 0.81 | CYP1A2 (0.44) | CYP11B1CYP11B2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7782726 | 0.81 | HCAR2 (0.38) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL7438606 | 0.78 | MLYCD (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL312495 | 0.77 | KDM4C (0.39) | CYP11B1CYP11B2HTTALDH1A1CYP2A6 | |
| SCHEMBL8499957 | 0.77 | L3MBTL1 (0.40) | SMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL7412278 | 0.77 | L3MBTL1 (0.40) | SMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL5793125 | 0.75 | KDM4E (0.34) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL643809 | 0.75 | CYP11B1 (0.37) | CYP11B1CYP11B2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL10439557 | 0.75 | CYP11B1 (0.37) | CYP11B1CYP11B2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL1006291 | 0.71 | TAAR1 (0.35) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1135377-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034254-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
| EP-0397365-B1 | Arylthiazolylimidazoles as 5HT3 Antagonists | PFIZER (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0397365-A1 | Arylthiazolylimidazoles as 5HT3 Antagonists | PFIZER INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| US-4914207-A | ANTIEMETICS | PFIZER INC. (US) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | CYP11B1 34/4885CYP11B2 32/4885SMN1; SMN2 3368/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | CYP11B1 25/4885CYP11B2 24/4885SMN1; SMN2 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.